# Franck Morschhauser

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/franck-morschhauser/

## Facts

| Field | Value |
| --- | --- |
| Citations | 34,883 |
| Field | Lymphoma Diagnosis and Treatment |
| h-index | 94 |
| i10-index | 384 |
| Last Known Institution | Centre Hospitalier Universitaire de Lille |
| OpenAlex ID | https://openalex.org/A5051605599 |
| ORCID iD | https://orcid.org/0000-0002-3714-9824 |
| Works | 921 |

## Researcher papers

- [Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial](https://scholariq.org/papers/brentuximab-vedotin-with-chemotherapy-for-cd30-positive-peripheral-t-cell/)
- [Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial](https://scholariq.org/papers/sequential-treatment-with-rituximab-followed-by-chop-chemotherapy-in-adult-b/)
- [Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma](https://scholariq.org/papers/rituximab-plus-lenalidomide-in-advanced-untreated-follicular-lymphoma/)
- [Safety and activity of the anti-CD79B antibody–drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study](https://scholariq.org/papers/safety-and-activity-of-the-anti-cd79b-antibody-drug-conjugate-polatuzumab/)
- [Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma](https://scholariq.org/papers/efficacy-and-tolerability-of-nivolumab-after-allogeneic-transplantation-for/)
- [Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network](https://scholariq.org/papers/primary-cns-lymphoma-at-first-relapse-progression-characteristics-management-and/)

## Researcher topics

- [Lymphoma Diagnosis and Treatment](https://scholariq.org/topics/lymphoma-diagnosis-and-treatment/)
- [Chronic Lymphocytic Leukemia Research](https://scholariq.org/topics/chronic-lymphocytic-leukemia-research/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Viral-associated cancers and disorders](https://scholariq.org/topics/viral-associated-cancers-and-disorders-2/)
- [CNS Lymphoma Diagnosis and Treatment](https://scholariq.org/topics/cns-lymphoma-diagnosis-and-treatment/)

## Researcher university

- [Centre Hospitalier Universitaire de Lille](https://scholariq.org/institutions/centre-hospitalier-universitaire-de-lille/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.